Biocon board to meet on strategic investment, fundraising plans

Biocon Limited's board of directors is scheduled to meet on Saturday, December 06, 2025, to discuss and approve key strategic proposals. The agenda includes an investment in Biocon Biologics Limited (BBL), an unlisted material subsidiary. This investment would involve purchasing or acquiring securities from BBL shareholders, potentially through cash or a consideration other than cash. This could be via the issuance and allotment of fully paid-up equity shares of Biocon Limited on a preferential allotment basis.

Additionally, the board will consider raising funds through various permissible modes. These include the issuance of commercial paper via private placement, and/or equity shares or other eligible securities. Potential methods for fund-raising encompass qualified institutions placement, rights issues, preferential issues, and further public offers, which could be executed in one or multiple tranches.

These proposals, if approved, will comply with applicable laws and may require shareholder approval at an extra-ordinary general meeting. The company has made this announcement to both BSE Limited and the National Stock Exchange of India Limited.